Focus area

Bio-convergence

Evolving biotech into an engineering discipline at the intersection of AI, hardware, and biology.

Celesta Capital invests in bio-convergence: compute, sensing, automation, and data science applied to improve scale and predictability in diagnostics, imaging, care delivery, and drug discovery.

Portfolio

  • 1Cell.Ai: A genomics-based Precision Oncology company.
  • 5C Network: Teleradiology platform connecting hospitals with on-demand radiologist reporting.
  • Alveo: Molecular diagnostic platform for rapid detection of infectious diseases.
  • Astranu: Next-generation ear imaging technology for clinical and consumer ear care.
  • Prellis: 3D printing of synthetic human tissues to advance drug discovery and development.
  • WhiteRabbit.ai: AI-driven imaging software for earlier breast cancer detection.

IPOs and exits

  • Berkeley Lights (IPO): Optofluidic platform for single-cell biology and biologics discovery.
  • Atonarp (exited): Miniaturized mass and optical spectrometry for clinical and industrial sensing.

Related reading